Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
Public ClinicalTrials.gov record NCT03517540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
Study identification
- NCT ID
- NCT03517540
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 193 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 10, 2018
- Primary completion
- Sep 14, 2020
- Completion
- Oct 14, 2020
- Last update posted
- Apr 28, 2022
2018 – 2020
United States locations
- U.S. sites
- 27
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Chandler | Arizona | 85224 | — |
| Novartis Investigative Site | North Little Rock | Arkansas | 72117 | — |
| Novartis Investigative Site | Coronado | California | 92118 | — |
| Novartis Investigative Site | Los Angeles | California | 90048 | — |
| Novartis Investigative Site | Los Angeles | California | 90057 | — |
| Novartis Investigative Site | Pasadena | California | 91105 | — |
| Novartis Investigative Site | Rialto | California | 92377 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30309 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30312 | — |
| Novartis Investigative Site | Marietta | Georgia | 30060 | — |
| Novartis Investigative Site | Chicago | Illinois | 60637-1470 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46237 | — |
| Novartis Investigative Site | Metairie | Louisiana | 70006 | — |
| Novartis Investigative Site | Shreveport | Louisiana | 71103 | — |
| Novartis Investigative Site | Concord | North Carolina | 28027 | — |
| Novartis Investigative Site | Durham | North Carolina | 27710 | — |
| Novartis Investigative Site | Morehead City | North Carolina | 28557 | — |
| Novartis Investigative Site | Providence | Rhode Island | 02905 | — |
| Novartis Investigative Site | Chattanooga | Tennessee | 37404 | — |
| Novartis Investigative Site | Germantown | Tennessee | 38138 | — |
| Novartis Investigative Site | Hermitage | Tennessee | 37076 | — |
| Novartis Investigative Site | Dallas | Texas | 75208-2312 | — |
| Novartis Investigative Site | San Antonio | Texas | 78215 | — |
| Novartis Investigative Site | Murray | Utah | 84107 | — |
| Novartis Investigative Site | Richmond | Virginia | 23249 | — |
| Novartis Investigative Site | Richmond | Virginia | 23298 | — |
| Novartis Investigative Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03517540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03517540 live on ClinicalTrials.gov.